imidazolone and Glucose-Intolerance

imidazolone has been researched along with Glucose-Intolerance* in 1 studies

Trials

1 trial(s) available for imidazolone and Glucose-Intolerance

Article	Year
Serum Levels of Protein-Bound Methylglyoxal-Derived Hydroimidazolone-1 are Independently Correlated with Asymmetric Dimethylarginine. Rejuvenation research, 2019, Volume: 22, Issue:5 Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase, being involved in endothelial dysfunction. Furthermore, ADMA levels have been shown to predict future cardiovascular events in patients with coronary risk factors, such as diabetes and hypertension. We have previously found that glyceraldehyde-derived advanced glycation end products (glycer-AGEs) stimulate ADMA generation Topics: Aged; Arginine; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Imidazoles; Inflammation; Male; Middle Aged; Protein Binding; Pyruvaldehyde; Vascular Stiffness	2019

Article

Year

Serum Levels of Protein-Bound Methylglyoxal-Derived Hydroimidazolone-1 are Independently Correlated with Asymmetric Dimethylarginine.

Rejuvenation research, 2019, Volume: 22, Issue:5

Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase, being involved in endothelial dysfunction. Furthermore, ADMA levels have been shown to predict future cardiovascular events in patients with coronary risk factors, such as diabetes and hypertension. We have previously found that glyceraldehyde-derived advanced glycation end products (glycer-AGEs) stimulate ADMA generation

Topics: Aged; Arginine; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Imidazoles; Inflammation; Male; Middle Aged; Protein Binding; Pyruvaldehyde; Vascular Stiffness

2019